A New Vasopressin V1a Antagonist Restores Social Behavior in the Mouse CNTNAP2KO Model of Autism

被引：0
|
作者：
Grundschober, Christophe [1 ]
Genet, Audrey [1 ]
Saxe, Michael [1 ]
Schnider, Patrick [1 ]
Biemans, Barbara [1 ]
机构：
[1] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
NEUROPSYCHOPHARMACOLOGY | 2017年 / 42卷
关键词：
Autism Spectrum Disorders; Vasopressin 1a Receptor Antagonist; Genetic Mouse Model; CNTNAP2;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
W42
引用
收藏
页码：S502 / S502
页数：1
相关论文
共 50 条
  • [1] A New Vasopressin V1a Antagonist Restores Normal Social Behavior and Reveals a Specific Brain Network in the Rat Valproate Model of Autism
    Grundschober, Christophe
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S62 - S63
  • [2] Exogenous and evoked oxytocin restores social behavior in the Cntnap2 mouse model of autism
    Penagarikano, Olga
    Lazaro, Maria T.
    Lu, Xiao-Hong
    Gordon, Aaron
    Dong, Hongmei
    Lam, Hoa A.
    Peles, Elior
    Maidment, Nigel T.
    Murphy, Niall P.
    Yang, X. William
    Golshani, Peyman
    Geschwind, Daniel H.
    SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (271)
  • [3] Conivaptan:: A dual receptor vasopressin V1a/V2 antagonist
    Ali, Farhan
    Raufi, M. Adnan
    Washington, Barbara
    Ghali, Jalal K.
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (03): : 261 - 279
  • [4] Vasopressin V1a receptor knockout mice exhibit impairment of social behavior
    Egashira, N
    Tanoue, A
    Matsuda, T
    Fuchigami, H
    Tsujimoto, G
    Mishima, K
    Iwasaki, K
    Fujiwara, M
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 100 : 206P - 206P
  • [5] Efficacy of the vasopressin V1A/V2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremia
    Ghali, JK
    Bisaha, JG
    Smith, N
    CIRCULATION, 2004, 110 (17) : 723 - 723
  • [6] Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors
    Mouillac, B
    Phalipou, S
    Cotte, N
    Balestre, MN
    Hibert, M
    Manning, M
    Barberis, C
    VASOPRESSIN AND OXYTOCIN: MOLECULAR, CELLULAR, AND CLINICAL ADVANCES, 1998, 449 : 359 - 361
  • [7] A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder
    Bolognani, Federico
    Rubido, Marta del Valle
    Squassante, Lisa
    Wandel, Christoph
    Derks, Michael
    Murtagh, Lorraine
    Sevigny, Jeff
    Khwaja, Omar
    Umbricht, Daniel
    Fontoura, Paulo
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (491)
  • [8] Pharmacological characterization of RWJ-676070, a dual vasopressin V1A/V2 receptor antagonist
    Gunnet, Joseph W.
    Wines, Pamela
    Xiang, Min
    Rybczynski, Philip
    Andrade-Gordon, Patricia
    de Garavilla, Lawrence
    Parry, Tom J.
    Cheung, Wai-man
    Minor, Lisa
    Demarest, Keith T.
    Maryanoff, Bruce E.
    Damiano, Bruce P.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 590 (1-3) : 333 - 342
  • [9] Pharmacotherapy for hyponatremia in heart failure:: Effects of a new dual V1A/V2 vasopressin antagonist YM087
    Abraham, WT
    Suresh, DP
    Wagoner, LE
    Haas, GJ
    McCord, J
    Rydzinski, S
    Nelson, CB
    Bakker-Arkema, RG
    CIRCULATION, 1999, 100 (18) : 299 - 299
  • [10] Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior
    Ferris, CF
    Lu, SF
    Messenger, T
    Guillon, CD
    Heindel, N
    Miller, M
    Koppel, G
    Bruns, FR
    Simon, NG
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2006, 83 (02) : 169 - 174
12345